Astrana Health (NASDAQ:ASTH – Free Report) had its price objective hoisted by Truist Financial from $50.00 to $59.00 in a research report report published on Friday morning, Benzinga reports. They currently have a buy rating on the stock.
A number of other equities analysts have also recently commented on ASTH. Stifel Nicolaus lifted their price target on Astrana Health from $48.00 to $60.00 and gave the stock a buy rating in a research note on Thursday, August 1st. Baird R W raised Astrana Health to a strong-buy rating in a research note on Thursday, May 30th. Finally, Robert W. Baird initiated coverage on Astrana Health in a research note on Thursday, May 30th. They issued an outperform rating and a $54.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of Buy and a consensus price target of $55.75.
Get Our Latest Research Report on ASTH
Astrana Health Price Performance
Astrana Health (NASDAQ:ASTH – Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.01. The business had revenue of $486.30 million during the quarter, compared to analyst estimates of $440.68 million. Astrana Health had a return on equity of 10.22% and a net margin of 4.29%. The company’s quarterly revenue was up 39.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.28 EPS. As a group, analysts forecast that Astrana Health will post 1.42 EPS for the current year.
About Astrana Health
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
See Also
- Five stocks we like better than Astrana Health
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- How to Calculate Options Profits
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.